Exelixis (EXEL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Voting matters and shareholder proposals
Clarifies the voting standard for Proposal No. 3 regarding the Amended 2017 Plan, requiring a majority of shares present or represented by proxy and entitled to vote for approval.
Abstentions will count as votes against Proposal No. 3, while broker non-votes will have no effect on the outcome.
Board of directors and corporate governance
The Board of Directors is soliciting proxies for the 2026 Annual Meeting scheduled for May 26, 2026.
Shareholder rights and capital structure
Shareholders may change or revoke their prior votes by following instructions provided in the proxy materials.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Exelixis
- Q1 2026 saw 10% revenue growth, strong cabozantinib sales, and zanzalintinib NDA progress.EXEL
Q1 20266 May 2026 - Zanzalintinib advances as a next-gen TKI amid strong growth and expanding oncology pipeline.EXEL
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Shareholders to vote on directors, auditor, equity plan, and pay amid strong growth and ESG focus.EXEL
Proxy filing15 Apr 2026 - Key votes include director elections, auditor ratification, and an equity plan share increase.EXEL
Proxy filing15 Apr 2026 - Zanzalintinib and CABOMETYX anchor growth in GI/GU oncology, with robust pipeline momentum.EXEL
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Zanza and new indications drive growth, targeting $2.4B revenue and leadership in key oncology markets.EXEL
The Citizens Life Sciences Conference 202611 Mar 2026 - Key RCC and CRC trials signal evolving standards and support double-digit growth outlook for 2026.EXEL
Leerink Global Healthcare Conference 202610 Mar 2026 - Strong 2025 growth led by cabozantinib, pipeline progress, and expanded stock repurchases.EXEL
Q4 202511 Feb 2026 - Q2 2024 revenues hit $637M, net income $226M, with CABOMETYX and pipeline progress leading growth.EXEL
Q2 20242 Feb 2026